2025
Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Cabel L, Lamy C, Keough K, Abbott C, Pouget N, Pierga J, Sablin M, Flavius J, Bronzini T, Laas E, Darrigues L, Feron J, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle S, Chen R, Le Tourneau C, Bidard F. Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2025, 43: 552-552. DOI: 10.1200/jco.2025.43.16_suppl.552.Peer-Reviewed Original ResearchTriple-negative breast cancerPathological complete responsePost-NACCtDNA detectionFollow-upPlasma ctDNADistant metastasisDistant relapse-free intervalPathological complete response statusPatients treated with NACTriple-negative breast cancer patientsEarly-stage TNBC patientsPost-surgical follow-upCtDNA-negative patientsCtDNA-positive patientsPost-neoadjuvant chemotherapyResidual disease levelsStratify survival outcomesImmune checkpoint inhibitorsNon-relapsing patientsRelapse-free intervalAdjuvant treatment decisionsMedian Follow-UpTumor-specific variantsMultivariate Cox model
2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Hortobagyi G, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. Journal Of The National Cancer Institute 2024, 117: 889-897. PMID: 39656951, PMCID: PMC12058262, DOI: 10.1093/jnci/djae314.Peer-Reviewed Original ResearchInvasive disease-free survivalHormone receptor-positiveRecurrence scoreRxPONDER trialClinical outcomesReceptor-positiveBreast cancerHER2-negative breast cancerNode-positive breast cancerDisease-free survivalMultivariate Cox modelBreast cancer outcomesBody mass indexHER2-negativePositive nodesTumor sizeSurvival outcomesClinicopathological characteristicsClinical characteristicsMass indexSelf-reported race/ethnicityCancer outcomesSecondary outcomesNHB womenTreatment efficacyLife's Essential 8 and Poor Brain Health Outcomes in Middle-Aged Adults
Clocchiatti-Tuozzo S, Rivier C, Renedo D, Huo S, Hawkes M, de Havenon A, Schwamm L, Sheth K, Gill T, Falcone G. Life's Essential 8 and Poor Brain Health Outcomes in Middle-Aged Adults. Neurology 2024, 103: e209990. PMID: 39442069, PMCID: PMC11498939, DOI: 10.1212/wnl.0000000000209990.Peer-Reviewed Original ResearchConceptsLife's Essential 8Poor cardiovascular healthCardiovascular healthBrain healthLife's Essential 8 scoreUnadjusted riskEssential 8Determinants of cardiovascular healthUK Biobank (UKBCardiovascular health profileModifiable cardiovascular risk factorsBrain health outcomesRisk factorsComposite outcomePublic health constructsPopulation studiesMiddle-aged adultsCox modelLate-life depressionCox proportional hazards modelsBrain health benefitsMultivariate Cox modelCardiovascular risk factorsFollow-up timeAoU participantsAssociation between the proportionality of functional mitral regurgitation and survival after mitral valve operation
Mori M, Waldron C, Ragnarsson S, Hosoba S, Zaky M, Lieu D, Krane M, Geirsson A. Association between the proportionality of functional mitral regurgitation and survival after mitral valve operation. JTCVS Open 2024, 22: 176-188. PMID: 39780834, PMCID: PMC11704552, DOI: 10.1016/j.xjon.2024.06.006.Peer-Reviewed Original ResearchTranscatheter edge-to-edge mitral repairMitral valve operationsFunctional mitral regurgitationMitral regurgitationHazard of deathEdge-to-edge mitral repairClinical relevanceMultivariate Cox proportional hazards modelCox modelMR groupMultivariate Cox modelCox proportional hazards modelsValve operationsAll-Cause MortalitySurgical patient populationHigher hazard of deathProportional hazards modelDisproportionate MRMitral operationsMitral repairIschemic MRMedian ageMR patientsFunctional MRNinety-dayAssociation of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502.
Gandhi S, Ballman K, Holmes M, Visvanathan K, Symington B, Carvan M, Matyka C, Weiss A, Winer E, Razaq W, Carey L, Partridge A, Chen W. Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502. Journal Of Clinical Oncology 2024, 42: 11016-11016. DOI: 10.1200/jco.2024.42.16_suppl.11016.Peer-Reviewed Original ResearchInvasive disease-free survivalBrief Pain InventoryPerceived Stress ScaleOverall survivalPittsburgh Sleep Quality IndexMultivariate Cox modelClinical outcomesBreast cancerCESD-RClinical trialsAssociated with worse clinical outcomesDouble-blind clinical trialCox modelBrief Pain Inventory scoresHormone receptor statusDisease-free survivalEpidemiologic Studies Depression Scale-RevisedCenter for Epidemiologic Studies Depression Scale-RevisedHigher Perceived Stress ScaleBody mass indexNonmetastatic breast cancerSleep qualityCESD-R scoresPerceived Stress Scale scoresPittsburgh Sleep Quality Index scoreCorrelation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.
Aung T, Zhang C, Espinoza G, Leung L, Moon J, Horst B, Ferringer T, Nastiuk K, Rimm D, Saenger Y. Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials. Journal Of Clinical Oncology 2024, 42: 9567-9567. DOI: 10.1200/jco.2024.42.16_suppl.9567.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesRecurrence free survivalAmerican Joint Committee on CancerFree survivalInfiltrating lymphocytesRetrospective cohortClinical trialsQuantify tumor-infiltrating lymphocytesStage II-III melanomaTumor-infiltrating lymphocytes groupDiagnostic slidesIIb-IIIaRoswell Park Comprehensive Cancer CenterEarly-stage melanoma patientsCox modelStage IIB-IIICAdjuvant clinical trialsKaplan-Meier curvesMultivariate Cox modelUnivariate Cox modelCox proportional hazards modelsClinical pathological featuresGeisinger Medical CenterProportional hazards modelClinical trial designInfluence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, PMCID: PMC12118599, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristics
2023
The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer
Liu L, Wang Y, Liu T, Rao S, Zeng M. The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer. Abdominal Radiology 2023, 48: 3653-3660. PMID: 37755476, DOI: 10.1007/s00261-023-04048-z.Peer-Reviewed Original ResearchConceptsLocally advanced gastric cancerLargest lymph nodeNeoadjuvant chemotherapyOverall survivalLong-term prognosisTumor responseLN respondersRadical surgeryLymph nodesLargest LNComputed tomographyLocally advanced gastric cancer patientsTumor response to NACTumor response to neoadjuvant chemotherapyGastric cancerResponse to NACResponse to neoadjuvant chemotherapyLN responsePrediction of tumor responseAssessment of tumour response to neoadjuvant chemotherapyPrimary tumor responseAssociated with OSAdvanced gastric cancerProspective clinical trialMultivariate Cox model
2021
Survival in male breast cancer (MaBC) over the past three decades.
Leone J, Freedman R, Leone J, Hassett M, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Survival in male breast cancer (MaBC) over the past three decades. Journal Of Clinical Oncology 2021, 39: 569-569. DOI: 10.1200/jco.2021.39.15_suppl.569.Peer-Reviewed Original ResearchBreast cancer-specific survivalOverall survivalBreast cancerCox modelWorse breast cancer-specific survivalHormone receptor-negative statusGrade 3 diseaseCancer-specific survivalEnd Results registryReceptor-negative statusYear of diagnosisMale breast cancerMultivariate Cox modelDecade of diagnosisPeriod of diagnosisBreast cancer mortalityProportional hazards regressionLog-rank testCause of deathPatient characteristicsMedian ageHazards regressionCancer mortalityKaplan-MeierBlack race
2020
Posttraumatic Stress Disorder, Antidepressant Use, and Hemorrhagic Stroke in Young Men and Women
Gaffey AE, Rosman L, Burg MM, Haskell SG, Brandt CA, Skanderson M, Dziura J, Sico JJ. Posttraumatic Stress Disorder, Antidepressant Use, and Hemorrhagic Stroke in Young Men and Women. Stroke 2020, 52: 121-129. PMID: 33297868, PMCID: PMC7770089, DOI: 10.1161/strokeaha.120.030379.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderHemorrhagic strokeHealth care utilizationUse of SSRIsGreater riskSSRI useStroke riskCare utilizationStress disorderEffects of PTSDIncident hemorrhagic strokeMiddle-aged veteransModifiable risk factorsNon-pharmacological treatmentMultivariate Cox modelNorepinephrine reuptake inhibitorsOverall incidence rateHemorrhagic stroke riskSNRI useIncident strokeAntidepressant useReuptake inhibitorsComorbid conditionsLifestyle factorsPsychiatric comorbidityClinic-Based Pediatric Disclosure Intervention Trial Improves Pediatric HIV Status Disclosure in Ghana.
Paintsil E, Kyriakides TC, Antwi S, Renner L, Nichols JS, Amissah K, Kusah JT, Alhassan A, Ofori IP, Catlin AC, Gan G, Lartey M, Reynolds NR. Clinic-Based Pediatric Disclosure Intervention Trial Improves Pediatric HIV Status Disclosure in Ghana. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 84: 122-131. PMID: 32049772, PMCID: PMC7138721, DOI: 10.1097/qai.0000000000002316.Peer-Reviewed Original ResearchConceptsTreatment groupsHIV disclosure interventionsHIV health careHIV-positive childrenMultivariate Cox modelDisclosure interventionHIV status disclosureBetter overall treatment effectHealth care providersYears of ageChild-caregiver dyadsOverall treatment effectModified intentionHIV clinicHIV statusIntervention armIntervention trialsStatus disclosureTreat approachCare providersCox modelTime pointsTherapeutic communicationControl participantsHealth care
2019
Posttraumatic Stress Disorder and Risk for Stroke in Young and Middle-Aged Adults
Rosman L, Sico JJ, Lampert R, Gaffey AE, Ramsey CM, Dziura J, Chui PW, Cavanagh CE, Brandt C, Haskell S, Burg MM. Posttraumatic Stress Disorder and Risk for Stroke in Young and Middle-Aged Adults. Stroke 2019, 50: 2996-3003. PMID: 31619151, DOI: 10.1161/strokeaha.119.026854.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIncident transient ischemic attackPosttraumatic stress disorderEffects of PTSDIschemic strokeIncident strokeHealthcare utilizationIncidence of TIAStress disorderYoung adultsMiddle-aged veteransStroke risk factorsMultivariate Cox modelIschemic stroke riskAge-specific prevention strategiesVeterans Health AdministrationMiddle-aged adultsIschemic attackStroke riskPsychological factorsUnadjusted analysesRisk factorsEffect modificationCox modelPsychiatric disorders
2018
What Predicts Mortality in Essential Tremor? A Prospective, Longitudinal Study of Elders
Zubair A, Cersonsky TEK, Kellner S, Huey ED, Cosentino S, Louis ED. What Predicts Mortality in Essential Tremor? A Prospective, Longitudinal Study of Elders. Frontiers In Neurology 2018, 9: 1077. PMID: 30581416, PMCID: PMC6292933, DOI: 10.3389/fneur.2018.01077.Peer-Reviewed Original ResearchRisk of mortalityGeriatric Depression ScaleEssential tremorHazard ratioCDR scoresFinal multivariate Cox modelHigher geriatric depression scaleLower Montreal Cognitive Assessment scoreUnivariate Cox regression modelOlder ageCox proportional hazards modelMontreal Cognitive Assessment scoreHigher Clinical Dementia Rating scorePredictors of mortalityClinical Dementia Rating scoreMultivariate Cox modelCox regression modelMean baseline ageDementia Rating scoreHigher CDR scoreProportional hazards modelCommon neurologic diseasesCognitive Assessment scoreIndependent predictorsMore fallsTransfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions
Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.Peer-Reviewed Original ResearchRBC transfusion independenceHMA initiationTransfusion independenceTransfusion dependenceLR-MDSClinical trial dataHypomethylating agentTransfusion statusMedian timeMedian TI durationCox modelContinuous Medicare Parts ATrial dataRed blood cell transfusionDiagnosis of MDSRBC transfusion dependenceSubset of ptsBlood cell transfusionEnd Results-MedicareErythropoiesis-stimulating agentsHigh-risk diseaseMultivariate Cox modelTreatment of MDSEnd of studyTI duration
2017
Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.
Lattanzi M, Lee Y, Robinson E, Weiss S, Moran U, Simpson D, Shapiro R, Berman R, Pavlick A, Wilson M, Kirchhoff T, Zhong J, Osman I. Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy. Journal Of Clinical Oncology 2017, 35: 9577-9577. DOI: 10.1200/jco.2017.35.15_suppl.9577.Peer-Reviewed Original ResearchMelanoma-specific survivalWorse melanoma-specific survivalHistologic subtypeNodular melanomaNYU cohortSEER cohortMetastatic settingSystemic therapyPrimary histologic subtypeCheckpoint inhibitor immunotherapyMultivariate Cox modelThick primary tumorsDifferent clinical behaviorPrimary nodular melanomaNext-generation sequencingSignificant predictorsClinical Trial ReportingLow mutational burdenMutational landscapeHigh mitotic indexSpecific survivalWorse prognosisClinical behaviorPrimary tumorMelanoma survivalAssociation Between Chronic Kidney Disease and Rates of Transfusion and Progression to End‐Stage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization—An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program
Vora A, Stanislawski M, Grunwald G, Plomondon M, Rumsfeld J, Maddox T, Vidovich M, Woody W, Nallamothu B, Gurm H, Rao S. Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to End‐Stage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization—An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program. Journal Of The American Heart Association 2017, 6: e004819. PMID: 28420645, PMCID: PMC5532998, DOI: 10.1161/jaha.116.004819.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood TransfusionCardiac CatheterizationDisease ProgressionFemaleFemoral ArteryHemorrhageHumansKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsPuncturesRadial ArteryRenal DialysisRenal Insufficiency, ChronicRetrospective StudiesRisk FactorsTime FactorsTransfusion ReactionTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsVeterans HealthConceptsChronic kidney diseaseClinical Assessment Reporting and TrackingDegree of CKDEnd-stage renal diseaseGlomerular filtration rateCardiac catheterizationHigh-risk populationTransradial accessPostprocedure transfusionTransfemoral accessRenal diseaseIncreased riskKidney diseaseBaseline glomerular filtration rateProgression to end-stage renal diseaseRate of blood transfusionDegree of renal dysfunctionRisk of progression to end-stage renal diseaseTransradial patientsLonger fluoroscopy timeRates of chronic kidney diseaseProgression to dialysisRate of transfusionAssociated with lower riskMultivariate Cox model
2016
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Di Leo A, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research 2016, 22: 5755-5764. PMID: 27185372, PMCID: PMC5124409, DOI: 10.1158/1078-0432.ccr-16-0148.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalBreast NeoplasmsDisease-Free SurvivalDouble-Blind MethodEpidermal Growth FactorEstradiolFemaleFulvestrantGene Expression ProfilingHepatocyte Nuclear Factor 3-alphaHumansMiddle AgedPostmenopauseReceptors, EstrogenSignal TransductionTranscription Factor AP-2TranscriptomeConceptsProgression-free survivalBreast cancerPredictive biomarkersCONFIRM studyMetastatic estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerGene signatureBiologic pathwaysAdvanced breast cancerMetastatic breast cancerMultivariate Cox modelPotential new therapeutic targetEstrogen receptor antagonistNew therapeutic targetsNegative predictive valuePrimary tumor samplesNovel gene signatureMetastatic ERPrimary ERReceptor antagonistFulvestrant treatmentDecreased responseCox modelER levelsPostoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database
Rimner A, Yao X, Huang J, Antonicelli A, Ahmad U, Korst RJ, Detterbeck F, Gomez DR. Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database. Journal Of Thoracic Oncology 2016, 11: 1785-1792. PMID: 27346413, PMCID: PMC5257334, DOI: 10.1016/j.jtho.2016.06.011.Peer-Reviewed Original ResearchConceptsPostoperative radiation therapyStage IIOS benefitRadiation therapyUse of PORTMasaoka-Koga stage IIInternational Thymic Malignancy Interest GroupStage II thymomaOverall survival benefitPrimary end pointMultivariate Cox modelLonger overall survivalLog-rank testIndividual patient dataImproved OSParaneoplastic syndromeOverall survivalSurvival benefitOS ratesHistologic subtypePatient populationRetrospective databaseUnivariate analysisCox modelThymoma
2015
Perinatal substance use: A prospective evaluation of abstinence and relapse
Forray A, Merry B, Lin H, Ruger JP, Yonkers KA. Perinatal substance use: A prospective evaluation of abstinence and relapse. Drug And Alcohol Dependence 2015, 150: 147-155. PMID: 25772437, PMCID: PMC4387084, DOI: 10.1016/j.drugalcdep.2015.02.027.Peer-Reviewed Original ResearchConceptsRates of abstinenceMean daysSubstance useMultivariate Cox modelLittle prospective dataPostpartum relapseRelapse postpartumAbstinence ratesProspective evaluationNicotine cigarettesProspective dataCox modelPregnancyRelapseCigarettesAbstinenceToxicology testingCocaineWomenPsychological treatmentLast monthPostpartumMarijuanaSpecific substancesDaysPatients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease
Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, Galsky M, Pomerantz M, Oh W. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal Of Urology 2015, 194: 91-97. PMID: 25623747, DOI: 10.1016/j.juro.2015.01.078.Peer-Reviewed Original ResearchConceptsDefinitive local therapyGleason 8 diseaseGleason score 8Gleason 9Increased risk of deathRadiation therapyLocal therapyRisk of deathIncreased riskGleason 8Radical prostatectomyScore 8Associated with higher prostate specific antigenPatients treated with radical prostatectomyBiopsy Gleason score 8Gleason 9-10 diseaseHigher prostate specific antigenNeoadjuvant/adjuvant androgen deprivation therapyAndrogen deprivation therapyHigh grade diseaseBaseline patient characteristicsProstate specific antigenMultivariate Cox modelMedian followupBiochemical recurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply